Introduction: Acute lymphoblastic leukaemia (ALL) is the most common malignancy in childhood.Although some prognostic factors have been defined to date, estimation of prognosis is currently not perfect.Previous studies have shown an association of FLT3 with poor prognosis and CCAAT/enhancer binding protein α (CEBPA) mutation with the development of acute myeloid leukaemia (AML).Here we aimed to evaluate the prognostic value of FLT3-ITD and CEBPA mutations in ALL. Materials and Method:Sixty-one patients with ALL were included in the study.Patients were divided into three risk groups according to BFM risk classification.All of the patients were examined for FLT3-ITD mutations and 45 of them for CEBPA mutations.Mutation positive and negative patients were compared in terms of their risk groups, translocations and cell lineage.The clinical courses of the patients were appraised.Results: FLT3-ITD mutation was detected in three of 61 patients, and CEBPA mutations were detected in 11 of 45 patients.The incidence of established prognostic indicators including BFM risk classification, t(9;22);BCR-ABL, t(1;19);E2A-PBX1, t(12;21);TEL-AML1, t(4;11);MLL-AF4 were similar between FLT3-ITD and CEBPA positive and negative patients.A patient with an FLT3-ITD mutation was very susceptible to pancytopenia after maintenance treatment and another two patients with FLT3-ITD mutations were more prone to febrile neutropenia. Conclusion:Our results suggest that CEBPA or FLT3-ITD mutations may not be related to ALL prognosis in Turkish patients.However, FLT3-ITD mutation may have an influence on the response of bone marrow to chemotherapy.

CEBPA

10.7727/wimj.2015.446

Cite

Citations (0)

Mesane çıkış obstrüksiyonu bulunan hastalarda non-invaziv yöntem olan "Near-Infrared Spectroscopy" (NIRS) uygulaması

Ni̇hat Arikan Murat Yurt

Source

Cite

Citations (0)

Reduced folat carrier gene status in colorectal, gastric, and pancreatic cancer

Journal of Clinical Oncology (2009)

Timuçin Çil Ahmet Tüzün Ayşe Altıntaş Sabri Batum Abdurrahman Işıkdoğan

e13540 Background: Folates play a key role in one-carbon metabolism essential for the biosynthesis of purines, thymidylate and hence DNA replication. Folates and antifolates which cannot traverse membranes must use specific transport systems for their cellular uptake. Antifolates such as raltitrexed and pemetrexed which will be used for gastrointestinal system cancer patients treatment are divalent anions which predominantly use the reduced folate carrier (RFC) for their cellular uptake. The aim of this prospective study; was documenting RFC gene status in gastric, colorectal and pancreatic cancers in southeast region of Turkey. Methods: We were evaluated homozygote, heterozygote mutations of RFC (SLC19A1) and wild type of RFC in new diagnosis gastric, colorectal and pancreas cancer patients who presented at the medical oncology and gastroenterology divisions of the Dicle University Hospital in Turkey between the dates August 2007 and October 2008 in southeast region of Turkey. Results: We were evaluated gene status of RFC in 62 (50%) colorectal, 45 (36.3%) gastric and 17 (13.7%) pancreatic cancer patients. In colorectal cancer patients group; 28 (45.9%), 19 (31.1%), 14 (23%), in gastric cancer 29 (64.4%), 7 (15.6%), 9 (20%), in pancreatic cancer 11 (64.7%), 2 (11.8%), 4 (23.5%) heterozygote, homozygote and wild type gene status, respectively. These results have no statistically significant (p=0.209) in three different gastrointestinal cancer types. Conclusions: New generation antifolat chemotherapeutic drugs such as pemetrexed which is multitargeted antifolat and enters the cells via the RFC system has demonstrated activity in gastrointestinal cancers. We think that antifolat drugs will be used in colorectal, gastric and pancreatic cancer patients in standard treatment protocols and RFC gene status will be an important of antifolat drugs activity in these tumors. No significant financial relationships to disclose.

Gastrointestinal cancer

Pemetrexed

10.1200/jco.2009.27.15_suppl.e13540

Cite

Citations (0)

PP-085 THE ROLE OF FLT3-ITD AND CEBPA MUTATIONS ON PROGNOSIS OF ACUTE LYMPHOBLASTIC LEUKEMIA IN TURKISH PATIENTS

Leukemia Research (2014)

I. Uluca Murat Söker Mustafa Ayyıldız Murat Yurt Velat Şen

CEBPA

10.1016/s0145-2126(14)70139-0

Cite

Citations (0)

MicroRNAs expression profiles as biomarkers and therapeutic tools in Turkish patients with chronic myeloid leukemia

Bratislavské lekárske listy/Bratislava medical journal (2020)

Murat Yurt Orhan Ayyıldız Abdullah Karakuş Ayşe Feyda Nursal Hilmi İsi

In 95 % of Chronic myeloid leukemia (CML) patients, chromosomal translocation resulting in the formation of the Philadelphia (Ph) chromosome (t:9;22) is observed, which in turn leads to the formation of the BCR-ABL fusion gene. MicroRNAs (miRNAs) are a group of small and non-coding RNAs modulating gene expression via binding to the target mRNAs. We aimed to characterize the expression profiles of various miRNAs in different stages of Ph(+) CML patients.This case-controlled study was conducted in 75 CML patients and 25 healthy controls. The subjects were categorized into 4 groups; newly diagnosed patients, treatment-response patients, treatment-failure patients, and healthy controls. Expressions of miRNAs was analyzed by RT-PCR.miR-150 expression was downregulated in the treatment failure patients compared to the control group (p = 0.003212) while miRNA 148b expression up-regulated in the treatment failure patients than the control group (p = 0.038016). miR-10a expression was up-regulated in newly diagnosed and treatment response patients compared to control group (p = 0.003934, p = 0.000292, respectively). It was found that miR-10a expression increased 11.17- fold in newly diagnosed patients and 9.82-fold in treatment response patients than in the control group.Our data suggest that expression profiles of miR-10a, miR-150, and miRNA 148b were correlated as biomarker and therapeutic tool in Turkish patients with CML (Tab. 2, Fig. 1, Ref. 30).

breakpoint cluster region

10.4149/bll_2020_023

Cite

Citations (6)

Diyarbakır bölgesinde Beta-Talasemi taramasında belirlenemeyen mutasyon tiplerinin dizi analizi yöntemiyle araştırılması

Murat Yurt

BETA (programming language)

Source

Cite

Citations (0)

Akut myeloid lösemili hastalarımızda t(8;21) ve inv (16)'nın kantitatif RT-PCR ile araştırılması

Orhan Ayyıldız Sevgi Kalkanlı Taş Sabri Batun Abdurrahman Işıkdoğan Murat Söker

Source

Cite

Citations (0)